Clinical Trials
6
Active:2
Completed:3
Trial Phases
3 Phases
Phase 1:4
Phase 2:1
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (66.7%)Phase 2
1 (16.7%)Phase 3
1 (16.7%)A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease
Phase 3
Active, not recruiting
- Conditions
- Chronic Graft-versus-host-disease
- Interventions
- First Posted Date
- 2024-02-16
- Last Posted Date
- 2025-07-10
- Lead Sponsor
- Incyte Biosciences Japan GK
- Target Recruit Count
- 21
- Registration Number
- NCT06263478
- Locations
- 🇯🇵
Fujita Health University Hospital, Aichi, Japan
🇯🇵University of Fukui Hospital, Fukui, Japan
🇯🇵Kyushu University Hospital, Fukuoka, Japan
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of INCB054707
- First Posted Date
- 2021-10-05
- Last Posted Date
- 2022-09-16
- Lead Sponsor
- Incyte Biosciences Japan GK
- Target Recruit Count
- 30
- Registration Number
- NCT05068466
- Locations
- 🇯🇵
Souseikai Fukuoka Mirai Hospital, Fukuoka, Japan
To Assess the Safety, Tolerability and Pharmacokinetics of INCB086550
- First Posted Date
- 2020-12-19
- Last Posted Date
- 2022-11-15
- Lead Sponsor
- Incyte Biosciences Japan GK
- Target Recruit Count
- 3
- Registration Number
- NCT04674748
- Locations
- 🇯🇵
National Cancer Center Hospital - East, Chiba, Japan
🇯🇵National Cancer Center Hospital, Tokyo, Japan
To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)
Phase 1
Active, not recruiting
- Conditions
- Non Hodgkins LymphomaDiffuse Large B-cell Lymphoma
- Interventions
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2025-07-16
- Lead Sponsor
- Incyte Biosciences Japan GK
- Target Recruit Count
- 72
- Registration Number
- NCT04661007
- Locations
- 🇯🇵
Aichi Cancer Center Hospital, Aichi, Japan
🇯🇵Chiba Cancer Center, Chiba, Japan
🇯🇵National Cancer Center Hospital East, Chiba, Japan
Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)
- First Posted Date
- 2020-06-17
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Incyte Biosciences Japan GK
- Target Recruit Count
- 42
- Registration Number
- NCT04434937
- Locations
- 🇯🇵
Ja-Aichi Anjo Kosei Hospital, Anjo, Japan
🇯🇵University of Fukui Hospital, Fukui, Japan
🇯🇵Jcho Kyushu Hospital, Fukuoka, Japan
- Prev
- 1
- 2
- Next
News
No news found